← Back to Compounds
oralanabolic

Oxymetholone

AnadrolA-bombsOxyAnapolon
320
Anabolic Ratio
45
Androgenic Ratio
0.38d
Half-Life

One of the most potent oral AAS ever developed. Originally prescribed for anemia and muscle-wasting diseases. Produces the fastest and most dramatic strength and mass gains of any oral compound. Severely hepatotoxic and strongly suppressive.

Mechanism of Action

17α-alkylated for oral bioavailability. Despite not aromatizing in the classical sense, it has intrinsic estrogenic activity at the ER, causing significant water retention and gynecomastia risk. Potent nitrogen retention via AR binding. Dramatically increases RBC production (EPO pathway) — originally FDA-approved for aplastic anemia (1961). Strong progestogenic activity contributes to suppression and mood effects.

Oxymetholone molecule
Molecular structure

Typical Dosing

175 mg
low / week
350 mg
moderate / week
700 mg
high / week

⚠ Warning Flags

  • Most hepatotoxic common oral AAS — never exceed 6 weeks
  • Severe water retention — not suitable for cutting
  • TUDCA/UDCA liver support mandatory
  • Estrogenic despite not aromatizing — AI may be insufficient; Nolvadex preferred

Effect Profile

Muscle Protein Synthesis
8Very High
Nitrogen Retention
8Very High
Strength Gains
8Very High
Red Blood Cell Production
8Very High
Fat Loss
1Minimal
Glycogen Storage
8Very High
Recovery Speed
7High
Collagen Synthesis
4Low

Side Effect Profile

Hormonal Suppression
7High
Estrogenic Effects
7High
Androgenic Effects
5Moderate
Cardiovascular Strain
7High
Liver Stress
8Very High
Insulin Resistance
4Low
Mood Changes
6Moderate
Prostate Risk
4Low

Research Studies

Anabolic effects of oxymetholone in men undergoing total hip replacement

Bross R, et al. · 1999

PubMed

Oxymetholone (100 mg/day) significantly increased lean body mass (+3.3 kg) and reduced fat mass in men recovering from total hip replacement, with notable increases in grip strength — confirming potent anabolic efficacy in a clinical setting.

Oxymetholone promotes weight gain in patients with advanced human immunodeficiency virus (HIV-1) infection

Hengge UR, et al. · 1996

PubMed

HIV patients receiving oxymetholone gained significantly more weight (predominantly lean mass) than placebo controls, establishing its role in wasting disease and documenting its anabolic potency at therapeutic doses.

Adverse events associated with testosterone replacement in middle-aged and older men

Calof OM, et al. · 2005

PubMed

Meta-analysis context: oxymetholone-class androgens are associated with significantly elevated hematocrit and polycythemia risk versus testosterone alone, underscoring EPO-axis stimulation.

A review of oxymetholone: a 17α-alkylated anabolic-androgenic steroid

Pavlatos AM, et al. · 2001

PubMed

Comprehensive clinical review documenting oxymetholone's profound anabolic effects (lean mass ↑5–10%), hepatotoxic profile (peliosis hepatis, hepatocellular carcinoma risk with long use), and hormonal suppression mechanisms.